Edenbridge selects PANTHERx to distribute Yargesa capsules

02 Apr 2024
www.pharmaceutical-technology.com
Edenbridge selects PANTHERx to distribute Yargesa capsules
Preview
Source: Pharmaceutical Technology
The capsule is intended for patients with Type 1 Gaucher disease. Credit: Sirikarn Rinruesee/Shutterstock.com.
Edenbridge Pharmaceuticals has selected PANTHERx Rare to distribute Yargesa (miglustat) capsules for the treatment of Type 1 Gaucher disease.
The medication represents the first oral treatment option for adults with mild to moderate disease who are unable to use enzyme replacement therapy.
The glucosylceramide synthase inhibitor Yargesa exerts its effects through the substrate reduction therapy process.
This treatment method lessens the accumulation of harmful glycosphingolipids, thereby reducing symptoms.
Gaucher disease is a rare genetic disorder characterised by a deficiency in the glucocerebrosidase enzyme, which leads to the build-up of a lipid known as glucosylceramide.
See Also:
Lonza Group gets grant for patent granted for capsule composition with pullulan, setting system, surfactant
Edenbridge selects PANTHERx to distribute Yargesa capsules
Preview
Source: Pharmaceutical Technology
MediciNova gets grant for ibudilast higher dosage oral tablet or capsule formulations
Edenbridge selects PANTHERx to distribute Yargesa capsules
Preview
Source: Pharmaceutical Technology
PANTHERx Rare Pharmacy CEO Rob Snyder stated: “We appreciate Edenbridge Pharmaceuticals’ commitment to making a difference in the lives of patients with Type 1 Gaucher disease.
“We are looking forward to serving the needs of the patients dealing with this illness, by streamlining the process associated with getting rare medications from the people who create them to the people who need them most, ultimately delivering better health outcomes to people living with rare diseases.”
In February 2024, Chiesi Global Rare Diseases, a Chiesi Group business unit, selected PANTHERx Rare for the distribution of Filsuvez topical gel.
Filsuvez topical gel treats wounds associated with dystrophic as well as junctional epidermolysis bullosa in adults and paediatric patients aged six months and above.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.